PMV Pharmaceuticals Inc
PMVP
NASDAQ
Biotechnology
$1.26
USD
+0.05 (+3.70%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $65.06M
Volume 189.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-78.34M
TTM
-28.7%
YoY
Operating Cash Flow
$-74.99M
TTM
-40.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.1 | 4.5 | 4.3 | 3.4 | 3.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 21.6 | 22.9 | 22.5 | 19.2 | 19.0 |
Operating Income | -21.6 | -22.9 | -22.5 | -19.2 | -19.0 |
EBITDA | -21.5 | -22.8 | -22.5 | -19.2 | -19.0 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 1.9 | 1.7 | 1.5 | 1.2 | 1.0 |
Income Before Income Taxes | -19.6 | -21.2 | -21.1 | -18.0 | -18.0 |
Income Taxes | -2.2 | 0.0 | -0.0 | 0.0 | 0.0 |
Net Income | -17.4 | -21.2 | -21.1 | -18.0 | -18.0 |
Consolidated Net Income / Loss | -17.4 | -21.2 | -21.1 | -18.0 | -18.0 |
Net Income Attributable to Common Shareholders | -17.4 | -21.2 | -21.1 | -18.0 | -18.0 |
Basic EPS | -$0.34 | -$0.41 | -$0.40 | -$0.34 | -$0.34 |
Diluted EPS | -$0.34 | -$0.41 | -$0.40 | -$0.34 | -$0.34 |
Basic Shares Outstanding | 52.0M | 52.0M | 53.0M | 53.2M | 53.3M |
Diluted Shares Outstanding | 52.0M | 52.0M | 53.0M | 53.2M | 53.3M |